Egypt -
engelsk -
EDA (Egyptian Drug Authority)
simvaxibe 10/10mg f.c. tabs.
pharma de france-egypt - coated tablet
Egypt -
engelsk -
EDA (Egyptian Drug Authority)
simvaxibe 10/40mg f.c. tabs.
pharma de france-egypt - coated tablet
Egypt -
engelsk -
EDA (Egyptian Drug Authority)
simvaxibe 10/20mg film coated tablets
pharma de france-egypt - tablet
Israel -
hebraisk -
Ministry of Health
סימבקסון 10
dexcel pharma technologies ltd - simvastatin - קפליות - simvastatin 10 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvaxon is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures - reduce the risk of stroke and transient ischemic attacks (tia's). hyperlipidemia: simvaxon is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvaxon therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hype
Israel -
hebraisk -
Ministry of Health
סימבקסון 40
dexcel pharma technologies ltd - simvastatin - קפליות - simvastatin 40 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvaxon is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures - reduce the risk of stroke and transient ischemic attacks (tia's). hyperlipidemia: simvaxon is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvaxon therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hype
Italia -
italiensk -
AIFA (Agenzia Italiana del Farmaco)
simvastatina hex. 20cpr 10mg
sandoz spa - simvastatina - compresse rivestite - "10 mg compresse rivestite con film" 20 compresse in blister pvc/al
Italia -
italiensk -
AIFA (Agenzia Italiana del Farmaco)
simvastatina hex. 28cpr 20mg
sandoz spa - simvastatina - compresse rivestite - "20 mg compresse rivestite con film" 28 compresse in blister pvc/al
Italia -
italiensk -
AIFA (Agenzia Italiana del Farmaco)
simvastatina hex. 28cpr 40mg
sandoz spa - simvastatina - compresse rivestite - "40 mg compresse rivestite con film" 28 compresse in blister pvc/al
Spania -
spansk -
AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
ezetimiba/simvastatina apotex 10 mg/20 mg comprimidos efg
apotex europe b.v. - simvastatina; ezetimiba - comprimido - 20 mg/10 mg - simvastatina 20 mg; ezetimiba 10 mg - simvastatina y ezetimiba
Spania -
spansk -
AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
ezetimiba/simvastatina apotex 10 mg/40 mg comprimidos efg
apotex europe b.v. - simvastatina; ezetimiba - comprimido - 40 mg/10 mg - simvastatina 40 mg; ezetimiba 10 mg - simvastatina y ezetimiba